Becton, Dickinson and Company (NYSE:BDX) declared a quarterly dividend on Monday, November 20th, RTT News reports. Stockholders of record on Friday, December 8th will be paid a dividend of 0.75 per share by the medical instruments supplier on Friday, December 29th. This represents a $3.00 annualized dividend and a dividend yield of 1.33%. The ex-dividend date of this dividend is Thursday, December 7th. This is a boost from Becton, Dickinson and’s previous quarterly dividend of $0.73.
Becton, Dickinson and has increased its dividend payment by an average of 10.1% per year over the last three years and has raised its dividend every year for the last 45 years. Becton, Dickinson and has a payout ratio of 28.2% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Becton, Dickinson and to earn $11.79 per share next year, which means the company should continue to be able to cover its $3.00 annual dividend with an expected future payout ratio of 25.4%.
Becton, Dickinson and (NYSE BDX) opened at $226.33 on Friday. Becton, Dickinson and has a 12-month low of $161.29 and a 12-month high of $229.68. The stock has a market capitalization of $51,170.00, a P/E ratio of 24.05, a P/E/G ratio of 1.79 and a beta of 1.04. The company has a debt-to-equity ratio of 1.44, a quick ratio of 5.03 and a current ratio of 5.58.
In other Becton, Dickinson and news, insider Gary M. Cohen sold 15,512 shares of the business’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the completion of the transaction, the insider now owns 95,781 shares in the company, valued at approximately $19,517,294.37. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Stephen Sichak sold 11,787 shares of the business’s stock in a transaction on Friday, September 8th. The stock was sold at an average price of $200.46, for a total value of $2,362,822.02. Following the transaction, the insider now owns 14,038 shares of the company’s stock, valued at approximately $2,814,057.48. The disclosure for this sale can be found here. Insiders own 1.40% of the company’s stock.
A number of research analysts recently issued reports on the company. Stifel Nicolaus restated a “buy” rating and set a $245.00 price objective on shares of Becton, Dickinson and in a research report on Friday, November 3rd. Morgan Stanley boosted their price objective on Becton, Dickinson and from $205.00 to $245.00 and gave the company an “equal weight” rating in a research report on Friday, November 3rd. Royal Bank Of Canada restated a “sector perform” rating and set a $230.00 price objective (up previously from $210.00) on shares of Becton, Dickinson and in a research report on Friday, November 3rd. Zacks Investment Research upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 price objective for the company in a research report on Tuesday, October 31st. Finally, Wells Fargo & Company restated a “positive” rating and set a $235.00 price objective (up previously from $225.00) on shares of Becton, Dickinson and in a research report on Tuesday, October 24th. They noted that the move was a valuation call. Four analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $217.08.
Becton, Dickinson and Company Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.